320 related articles for article (PubMed ID: 20142590)
1. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.
Burchert A; Müller MC; Kostrewa P; Erben P; Bostel T; Liebler S; Hehlmann R; Neubauer A; Hochhaus A
J Clin Oncol; 2010 Mar; 28(8):1429-35. PubMed ID: 20142590
[TBL] [Abstract][Full Text] [Related]
2. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
[TBL] [Abstract][Full Text] [Related]
3. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
Koskenvesa P; Kreutzman A; Rohon P; Pihlman M; Vakkila E; Räsänen A; Vapaatalo M; Remes K; Lundán T; Hjorth-Hansen H; Vakkila J; Simonsson B; Mustjoki S; Porkka K
Eur J Haematol; 2014; 92(5):413-20. PubMed ID: 24372965
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
Burchert A; Wölfl S; Schmidt M; Brendel C; Denecke B; Cai D; Odyvanova L; Lahaye T; Müller MC; Berg T; Gschaidmeier H; Wittig B; Hehlmann R; Hochhaus A; Neubauer A
Blood; 2003 Jan; 101(1):259-64. PubMed ID: 12393722
[TBL] [Abstract][Full Text] [Related]
5. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
6. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C; Guilhot J; Nicolini FE; Guerci-Bresler A; Rigal-Huguet F; Maloisel F; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Rea D; Jourdan E; Allard C; Delmer A; Rousselot P; Legros L; Berger M; Corm S; Etienne G; Roche-Lestienne C; Eclache V; Mahon FX; Guilhot F; ;
N Engl J Med; 2010 Dec; 363(26):2511-21. PubMed ID: 21175313
[TBL] [Abstract][Full Text] [Related]
7. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia.
Burchert A; Saussele S; Eigendorff E; Müller MC; Sohlbach K; Inselmann S; Schütz C; Metzelder SK; Ziermann J; Kostrewa P; Hoffmann J; Hehlmann R; Neubauer A; Hochhaus A
Leukemia; 2015 Jun; 29(6):1331-5. PubMed ID: 25712735
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Müller MC; Gattermann N; Lahaye T; Deininger MW; Berndt A; Fruehauf S; Neubauer A; Fischer T; Hossfeld DK; Schneller F; Krause SW; Nerl C; Sayer HG; Ottmann OG; Waller C; Aulitzky W; le Coutre P; Freund M; Merx K; Paschka P; König H; Kreil S; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Dec; 17(12):2392-400. PubMed ID: 14523462
[TBL] [Abstract][Full Text] [Related]
9. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Branford S; Rudzki Z; Harper A; Grigg A; Taylor K; Durrant S; Arthur C; Browett P; Schwarer AP; Ma D; Seymour JF; Bradstock K; Joske D; Lynch K; Gathmann I; Hughes TP
Leukemia; 2003 Dec; 17(12):2401-9. PubMed ID: 14523461
[TBL] [Abstract][Full Text] [Related]
10. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
[TBL] [Abstract][Full Text] [Related]
12. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
Malagola M; Breccia M; Skert C; Cancelli V; Soverini S; Iacobucci I; Cattina F; Liberati AM; Tiribelli M; Annunziata M; Trabacchi E; De Vivo A; Castagnetti F; Martinelli G; Fogli M; Stagno F; Pica G; Iurlo A; Pregno P; Abruzzese E; Pardini S; Bocchia M; Russo S; Pierri I; Lunghi M; Barulli S; Merante S; Mandelli F; Alimena G; Rosti G; Baccarani M; Russo D
Am J Hematol; 2014 Feb; 89(2):119-24. PubMed ID: 24122886
[TBL] [Abstract][Full Text] [Related]
13. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
Simonsson B; Gedde-Dahl T; Markevärn B; Remes K; Stentoft J; Almqvist A; Björeman M; Flogegård M; Koskenvesa P; Lindblom A; Malm C; Mustjoki S; Myhr-Eriksson K; Ohm L; Räsänen A; Sinisalo M; Själander A; Strömberg U; Bjerrum OW; Ehrencrona H; Gruber F; Kairisto V; Olsson K; Sandin F; Nagler A; Nielsen JL; Hjorth-Hansen H; Porkka K;
Blood; 2011 Sep; 118(12):3228-35. PubMed ID: 21685374
[TBL] [Abstract][Full Text] [Related]
14. Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha.
El Eit RM; Iskandarani AN; Saliba JL; Jabbour MN; Mahfouz RA; Bitar NM; Ayoubi HR; Zaatari GS; Mahon FX; De Thé HB; Bazarbachi AA; Nasr RR
Int J Cancer; 2014 Feb; 134(4):988-96. PubMed ID: 23934954
[TBL] [Abstract][Full Text] [Related]
15. Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.
Ishikawa I; Kato C; Harigae H; Sugawara T; Tomiya Y; Yamada M; Ishizawa K; Kameoka J; Miyamura K; Sasaki T
Tohoku J Exp Med; 2006 Dec; 210(4):355-63. PubMed ID: 17146202
[TBL] [Abstract][Full Text] [Related]
16. Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
Nicolini FE; Hayette S; Legros L; Rousselot P; Maloisel F; Tulliez M; Guerci A; Charbonnier A; Prébet T; Rigal-Huguet F; Chabane K; Magaud JP; Paillet C; Pivot C; Michallet M
Leuk Res; 2011 Jan; 35(1):80-6. PubMed ID: 20605207
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
Alimena G; Breccia M; Luciano L; Quarantelli F; Diverio D; Izzo B; De Angelis B; Mancini M; Latagliata R; Carmosino I; Nanni M; Picardi M; Rotoli B; Mandelli F; Pane F
Leuk Res; 2008 Feb; 32(2):255-61. PubMed ID: 17692911
[TBL] [Abstract][Full Text] [Related]
19. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
20. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
